(R) -8- (3-Amino-piperidin-1-yl) -7-ma-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl) -3

Linagliptin Linagliptin, nke Boehringer Ingelheim mepụtara, bụ nke FDA kwadoro na Mee 2, 2011. A na-eji ya jikọta nri na mmega ahụ iji meziwanye njikwa nke ọkwa glucose ọbara n'ime ndị nwere ụdị ọrịa shuga 2.Linagliptin na-eme ka njikwa glucose ọbara dị n'ọbara n'ime ndị ọrịa site na igbochi dipeptidyl peptidase-4 (DPP-4).

Incretin (Incretin) nwere mmetụta nke ịkwalite mmepụta insulin site na sel B nke pancreatic, ọkachasị gụnyere glucose-based insulinotropic polypeptide (GIP) na glucagon-dị ka polypeptide-1 (GLP-1).DDP-4 bụ serine protease dị n'elu sel.Ọ na-ejikọta na protein ma dị na plasma na anụ ahụ dị iche iche dị n'ime ahụ (dịka akụrụ, imeju, obere eriri afọ villi, sel endothelial, wdg).Linagliptin bụ onye na-emechi DPP-4 nke na-egbochi ọrụ nke enzyme site na ijikọ ya na DPP-4, na-egbu oge mmebi nke GLP-1, na-akwalite ọrụ GLP-1, ma na-akpali insulin na-adabere na glucose. na-ebelata ọkwa nke glucagon na mgbasa, si otú a na-ahazi ọkwa glucose ọbara nke ndị ọrịa nwere ụdị ọrịa shuga 2.

E jiri ya tụnyere ndị na-egbochi DPP-4 ndị ọzọ, uru bụ isi nke Linagliptin bụ: ọ nwere nchekwa akụrụngwa dị mma ma nwee ike ibelata haemoglobin glycosylated nke ọma.A na-ewepụ Linagliptin na nsị n'ụdị prototype.Mgbe nchịkwa ọnụ gasịrị, excretion gbasara akụrụ bụ naanị 5% nke ego a na-enye.Ọbụlagodi na a na-enye ya n'ime intravenous, naanị 30.8% ka a na-esi na akụrụ pụta.Ya mere, ọ dịghị mkpa maka ndị ọrịa na-enweta ọgwụgwọ.Na-elele ọrụ imeju na akụrụ mgbe niile yana mmezi dose.Ndị ọrịa niile nwere ike idozi dose ahụ n'otu n'otu maka ndenye ọgwụ dị mfe.
Mmeghachi omume ọjọọ nke Linagliptin na-emekarị bụ ọrịa iku ume, mgbachi imi, mgbu ahụ, isi ọwụwa na akpịrị akpịrị.